ScholarIQanswers from OpenAlex & ORCID
Helena A. Yu
ResearcherPublications, citations & collaboration network
Helena A. Yu is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Helena A. Yu have?
ScholarIQindexed works
Helena A. Yu has 651 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Helena A. Yu have?
ScholarIQcitation count
Helena A. Yu has 17,705 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Helena A. Yu?
ScholarIQh-index
Helena A. Yu has an h-index of 59 in OpenAlex.
What is the i10-index of Helena A. Yu?
ScholarIQi10-index
Helena A. Yu has an i10-index of 153 in OpenAlex.
What is the ORCID of Helena A. Yu?
ScholarIQorcid
The ORCID for Helena A. Yu is on the source record.
What is the OpenAlex record for Helena A. Yu?
ScholarIQopenalex
The OpenAlex for Helena A. Yu is on the source record.
What are the most-cited papers on Helena A. Yu?
ScholarIQmost cited works
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with <i>EGFR</i> -Mutant Lung Cancers
Helena A. Yu, Maria E. Arcila, Natasha Rekhtman, Camelia S. Sima, Maureen F. Zakowski, William Pao, Mark G. Kris, Vincent A. Miller, Marc Ladanyi, Gregory J. Riely
Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
Emmet Jordan, Hyunjae R. Kim, Maria E. Arcila, David Barron, Debyani Chakravarty, Jianjiong Gao, Matthew T. Chang, Ai Ni, Ritika Kundra, Philip Jonsson, Gowtham Jayakumaran, Sizhi Paul Gao, Hannah C. Johnsen, Aphrothiti J. Hanrahan, Ahmet Zehir, Natasha Rekhtman, Michelle S. Ginsberg, Bob T. Li, Helena A. Yu, Paul K. Paik, Alexander Drilon, Matthew D. Hellmann, Dalicia N. Reales, Ryma Benayed, Valerie W. Rusch, Mark G. Kris, Jamie E. Chaft, José Baselga, Barry S. Taylor, Nikolaus Schultz, Charles M. Rudin, David M. Hyman, Michael F. Berger, David B. Solit, Marc Ladanyi, Gregory J. Riely
Response to MET Inhibitors in Patients with Stage IV Lung Adenocarcinomas Harboring <i>MET</i> Mutations Causing Exon 14 Skipping
Paul K. Paik, Alexander Drilon, Pang‐Dian Fan, Helena A. Yu, Natasha Rekhtman, Michelle S. Ginsberg, Laetitia Borsu, Nikolaus Schultz, Michael F. Berger, Charles M. Rudin, Marc Ladanyi
Lineage plasticity in cancer: a shared pathway of therapeutic resistance
Àlvaro Quintanal-Villalonga, Joseph M. Chan, Helena A. Yu, Dana Pe’er, Charles L. Sawyers, Triparna Sen, Charles M. Rudin
<i>EGFR</i> -Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes
Nicolas Marcoux, Scott Gettinger, Grainne M. O’Kane, Kathryn C. Arbour, Joel W. Neal, Hatim Husain, Tracey L. Evans, Julie R. Brahmer, Alona Muzikansky, Philip Bonomi, Salvatore Del Prete, Anna Wurtz, Anna F. Farago, Dora Dias‐Santagata, Mari Mino–Kenudson, Karen L. Reckamp, Helena A. Yu, Heather A. Wakelee, Frances A. Shepherd, Zofia Piotrowska, Lecia V. Sequist